Join

Compare · ARGX vs IBRX

ARGX vs IBRX

Side-by-side comparison of argenx SE (ARGX) and ImmunityBio Inc. (IBRX): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both ARGX and IBRX operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
  • ARGX is the larger of the two at $54.76B, about 7.3x IBRX ($7.51B).
  • Over the past year, ARGX is up 51.2% and IBRX is up 109.2% - IBRX leads by 57.9 points.
  • IBRX has been more active in the news (10 items in the past 4 weeks vs 5 for ARGX).
  • ARGX has more recent analyst coverage (25 ratings vs 6 for IBRX).
PerformanceARGX+51.24%IBRX+109.18%
2025-06-09+0.00%2026-06-08
MetricARGXIBRX
Company
argenx SE
ImmunityBio Inc.
Price
$882.63-1.03%
$7.17+3.68%
Market cap
$54.76B
$7.51B
1M return
+12.11%
-7.42%
1Y return
+51.24%
+109.18%
Sector
Health Care
Health Care
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Biological Products (No Diagnostic Substances)
Exchange
NASDAQ
NASDAQ
IPO
2017
2015
News (4w)
5
10
Recent ratings
25
6
ARGX

argenx SE

argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.À.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.

IBRX

ImmunityBio Inc.

ImmunityBio, Inc., a clinical-stage immunotherapy company, develops cell and immune therapies to treat cancers and infectious diseases. The company develops Anktiva (N-803), an IL-15 superagonist and PD-L1 that activates natural killer and T effector cells in combination with chemo and trodelvy to treat cancers, such as merkel cell carcinoma, advanced pancreatic cancer, and advanced triple negative breast cancer; and an albumin-linked formulation of doxorubicin (Aldoxorubicin) to treat breast cancer, hodgkin lymphoma, SCLC, sarcoma, and glioblastoma. It also develops a memory T-cell cancer vaccine to deliver tumor-associated antigens and neoepitopes; and a human adenovirus 5 COVID-19 vaccine. The company was founded in 2014 and is based in San Diego, California.

Latest ARGX

Latest IBRX